Search on Site

Explore our comprehensive database of pharmaceutical news releases, press releases, events, and industry insights with ease. Effortlessly find relevant information tailored to your interests and stay updated on the latest developments in the pharmaceutical sector. Start searching now to uncover valuable insights and resources for your pharmaceutical endeavors.

Avanzanite Announces an Exclusive Agreement to License and Market Zemcelpro® in Europe

donors in adult patients with acute leukemias and myelodysplastic syndromes (MDS). The study is intended to provide confirmatory evidence of efficacy and safety and could support a possible indication expansion. “This partnership reflects why...

Niagen Bioscience Launched Niagen™ Plus Liquid At-Home Injections to Support Its Telehealth Expansion

self-reported outcomes were associated with reduced fatigue and improved sleep and skin. These findings require confirmation in larger, placebo-controlled studies (Nkrumah-Elie et al., 2026; Russ et al., 2026). “The liquid Niagen At-Home Injection...

Aptar Appoints Pharma Packaging Veteran Virginie Maes as President of its Pharma Business

performance and building highly engaged teams. Earlier in her career, Maes worked at McKinsey & Company, Terra Firma Capital Partners and Morgan Stanley. She holds an MBA from Harvard Business School, a Master’s in Financial Management from Vlerick...

StimCardio’s NeuroPulse Study Reports a Substantial Reduction in Recurrent Atrial Fibrillation Events Following Ablation Using Non-Invasive Wearable Neuromodulation

ablation may offer a fundamentally different way to approach that remaining challenge. These findings warrant confirmation in a larger multi-center clinical trial." StimCardio is developing Rhyvive™, an investigational, physician-prescribed,...

Karyopharm Files Supplemental New Drug Application with FDA for XPOVIO® (Selinexor) in Combination with Ruxolitinib for the Treatment of Myelofibrosis

to traditional approval and expects to continue working with the FDA during its review of the sNDA to finalize the confirmatory evidence plan. Karyopharm expects to receive notice of the FDA's decision on sNDA filing acceptance and, if accepted,...

U.S. FDA Approves Ziihera® (zanidatamab-hrii), With or Without Tislelizumab Plus Chemotherapy, for the First-Line Treatment of HER2-Positive Advanced Gastroesophageal Adenocarcinoma

Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).7 Ziihera is also approved in the European Union and other countries. Zanidatamab is being developed in...

BioVigil Reaches 1 Billion Hand Hygiene Opportunities, Marking a Major Milestone in Patient Safety and Infection Prevention

entry and exit events by user. A green light on the badge reinforces accountability and provides patients with visible confirmation of adherence at the point of care. Real time correction. Audible, vibratory and visual cues prompt immediate...

BioMarin's Supplemental New Drug Application for Full Approval of VOXZOGO® (vosoritide) for Children With Achondroplasia Accepted by the U.S. Food and Drug Administration

growth velocity. Continued approval may be contingent upon verification and description of clinical benefit in confirmatory trial(s). To fulfill this post-marketing requirement, BioMarin intends to use the ongoing open-label extension studies...

Cannabix Technologies and Omega Laboratories Announce a DOT-Like Breath-Based Drug Testing Panel for Recent-Use Detection

in breath gives customers a practical path to focus on recent use while maintaining the forensic quality, laboratory confirmation, and defensibility they expect from Omega." Omega's laboratory-based breath testing is performed using mass...

CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) Receives U.S. FDA Approval for an Additional Indication in Children and Adolescents Aged 2–17 Years at Increased Risk for Pneumococcal Disease

Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. “Children and adolescents with certain chronic conditions are at an increased risk for pneumococcal disease,...

Lundbeck Receives Marketing Authorization in South Korea for Vyepti® (eptinezumab) for the Preventive Treatment of Migraine

to CGRP and was intentionally designed for intravenous (IV) administration. The decision is based on results from the confirmatory Phase 3 trials PROMISE-1, PROMISE-2, DELIVER and SUNRISE. The latter trial, SUNRISE, was a randomized,...

BIZENGRI® (Zenocutuzumab-zbco) Wins FDA Approval for NRG1 Fusion-Positive Cholangiocarcinoma, Says Partner Therapeutics

Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). Infusion-Related Reactions/Hypersensitivity/Anaphylactic Reactions BIZENGRI can cause serious and...

Gilead’s Livdelzi® Shows Sustained Efficacy in PBC, Reducing ALP, Relieving Itch, and Potentially Slowing Disease Progression

Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s). Limitations of Use: Use of Livdelzi is not recommended in patients who have or develop decompensated cirrhosis...

Jazz Pharmaceuticals announces the U.S. FDA approval of Modeyso™ (dordaviprone) as the first and only treatment for recurrent H3 K27M-mutant diffuse midline glioma

for this indication may be contingent upon verification and description of clinical benefit in the Phase 3 ACTION confirmatory trial. Modeyso is the first and only treatment option approved by the FDA for this ultra-rare and aggressive brain tumor...

Kashiv BioSciences Announces Positive Topline Results from the Confirmatory Efficacy Study of ADL-018, a Biosimilar Candidate to XOLAIR® (omalizumab).

Kashiv BioSciences, LLC announced positive topline results from its confirmatory clinical efficacy and safety clinical trial evaluating ADL-018, a proposed biosimilar to XOLAIR® (omalizumab). The randomized, double-blind, multicenter study...

Neurophet gains FDA 510(k) clearance for Neurophet AQUA, advancing multiple sclerosis analysis with AI-driven precision

diagnosis and disease monitoring, and the McDonald criteria, the diagnostic criteria for MS, specifically includes MRI confirmation of lesions disseminated in space and time," said Jake Junkil Been, Co-CEO of Neurophet. "Neurophet AQUA's advanced...

Gilead’s Livdelzi (Seladelpar) receives FDA accelerated approval for primary biliary cholangitis

of Livdelzi for the approved indication may be contingent on verification and description of clinical benefit in confirmatory trial(s). “More people are being diagnosed with PBC, impacting people of varied ages, gender, race and ethnicity. Those...

FDA Grants Second Approval for EPKINLY® (epcoritamab-bysp) to Treat Relapsed or Refractory Follicular Lymphoma

Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). "The FDA approval of EPKINLY offers a new treatment option for relapsed or refractory follicular lymphoma,...

Beckman Coulter's DxI 9000 Immunoassay Analyzer

assays. Recently, tests for Hepatitis B and C viruses — namely Access anti-HCV, Access HBsAg, and Access HBsAg Confirmatory assays — received CE marks. Detection of the viral surface antigen (HBsAg) in serum or plasma indicates an infection caused...

Editorial Guidelines | Pharmaceutical-Era.com

with your submission. Abstract: Provide a brief abstract summarizing the key points of your content. Approval: Await confirmation from our editorial team before considering your content as published. We will notify you once the review process is...

Results 1 - 20 of 20